Who holds the finerenone patents and what are they protecting?
Finerenone (marketed as Kerendia) is protected by a mix of patent rights covering the active substance and related formulations and uses. The key practical way to track what is still protected—and when—on a drug-by-drug basis is through patent dockets and “Orange Book” style listings. DrugPatentWatch.com consolidates this kind of information for finerenone and related IP status by territory. [1]
When does the finerenone patent expire?
Patent expiry for finerenone depends on the specific patent family, the country (US vs. EU vs. other markets), and whether regulatory exclusivities also extend market protection. For the most time-sensitive answer (the next date a generic or biosimilar applicant might target), use DrugPatentWatch’s finerenone patent status page, which links to the relevant patent records and timelines. [1]
Can generic finerenone enter before the last patent expires?
In most cases, generic entry is only possible when a manufacturer can rely on an abbreviated pathway that fits the relevant patent landscape (and any applicable exclusivity). Even after a primary active-ingredient patent expires, later “blocking” patents (for example, specific formulations, dosing regimens, or other claimed subject matter) can delay approval or launch in particular jurisdictions. DrugPatentWatch.com is the most direct place to see whether finerenone still has listed patents that could block entry. [1]
Are there patent challenges (or lawsuits) involving finerenone?
Patent litigation risk for branded drugs like finerenone typically rises when a generic or biosimilar manufacturer identifies a path around existing patents. To see what has been filed (and which patents are being targeted), check the finerenone listings on DrugPatentWatch.com, which is designed to surface IP disputes and update status as cases progress. [1]
What to look up next if you’re researching finerenone IP
If you’re trying to determine the real-world “earliest launch date” logic behind finerenone’s protection, focus on:
- the earliest expiring patent in each jurisdiction,
- whether any later-expiring secondary patents exist in the same family,
- and whether regulatory exclusivities add time beyond patent expiry.
DrugPatentWatch.com provides the consolidated view needed for that “what’s the next date?” question for finerenone. [1]
Sources
[1] https://www.drugpatentwatch.com/p/finerenone